CA2294448A1 - Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins - Google Patents

Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins Download PDF

Info

Publication number
CA2294448A1
CA2294448A1 CA002294448A CA2294448A CA2294448A1 CA 2294448 A1 CA2294448 A1 CA 2294448A1 CA 002294448 A CA002294448 A CA 002294448A CA 2294448 A CA2294448 A CA 2294448A CA 2294448 A1 CA2294448 A1 CA 2294448A1
Authority
CA
Canada
Prior art keywords
pharmaceutical combination
combination preparations
preparations containing
erythropoietin
haemoglobins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002294448A
Other languages
French (fr)
Other versions
CA2294448C (en
Inventor
Paul Lehmann
Michael-Harold Town
Jurgen Feuerstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics Gmbh
Paul Lehmann
Michael-Harold Town
Jurgen Feuerstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh, Paul Lehmann, Michael-Harold Town, Jurgen Feuerstein filed Critical Roche Diagnostics Gmbh
Publication of CA2294448A1 publication Critical patent/CA2294448A1/en
Application granted granted Critical
Publication of CA2294448C publication Critical patent/CA2294448C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to pharmaceutical combination preparations containing erythropoietin and one or several modified haemoglobins.
The inventive combination preparations ase used especially for treating manifest anaemia. The inventive pharmaceutical combination preparation comprises a) individual forms of administration of an erythropoietin preparation suitable for an individual dose of a quantity of 3,000 - 7,000 U of the active agent and b) 50 - 100 ml of one or several modified haemoglobins. The erythropoietin preparation and the modified haemoglobin can be provided in separate or single forms of administration.
CA002294448A 1997-06-21 1998-06-03 Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins Expired - Lifetime CA2294448C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97110168A EP0885613A1 (en) 1997-06-21 1997-06-21 Use of modified hemoglobins for treatment of anemias and erythropoietin and modified hemoglobin containing combined preparations
EP97110168.8 1997-06-21
PCT/EP1998/003299 WO1998058660A1 (en) 1997-06-21 1998-06-03 Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins

Publications (2)

Publication Number Publication Date
CA2294448A1 true CA2294448A1 (en) 1998-12-30
CA2294448C CA2294448C (en) 2007-12-11

Family

ID=8226937

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294448A Expired - Lifetime CA2294448C (en) 1997-06-21 1998-06-03 Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins

Country Status (15)

Country Link
US (3) US6440932B1 (en)
EP (2) EP0885613A1 (en)
JP (3) JP2002504913A (en)
KR (1) KR100519904B1 (en)
CN (1) CN1185010C (en)
AT (1) ATE272405T1 (en)
AU (1) AU743475B2 (en)
BR (1) BR9810267A (en)
CA (1) CA2294448C (en)
DE (1) DE59811768D1 (en)
DK (1) DK0996462T3 (en)
ES (1) ES2226151T3 (en)
PT (1) PT996462E (en)
TR (1) TR199903192T2 (en)
WO (1) WO1998058660A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645733B2 (en) 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000514092A (en) * 1997-03-18 2000-10-24 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical combination preparation comprising erythropoietin and iron preparation
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
PT1311285E (en) * 2000-05-15 2005-06-30 Hoffmann La Roche Liquid pharmaceutical composition containing a derivative of erythropoietin
CA2431964C (en) 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
DE10215315A1 (en) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human transferrin for the treatment of anemia of chronic disease (ACD) and functional iron deficiency
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
KR101304081B1 (en) 2006-08-04 2013-09-05 프로롱 파마슈티컬스, 엘엘씨 Modified erythropoietin
AR067537A1 (en) * 2007-07-17 2009-10-14 Hoffmann La Roche PURIFIED POLYPEPTIDES PURIFICATION
CL2008002054A1 (en) 2007-07-17 2009-05-29 Hoffmann La Roche Method for the regeneration of a cation exchange chromatography column after elusion of monopeglated erythropoietin and method to obtain a monopeglated erythropoietin, incorporating the regeneration method of the cation exchange column.
EP3789395A1 (en) 2015-11-23 2021-03-10 Bristol-Myers Squibb Company Pegylation of fgf21

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
NO881507D0 (en) * 1987-04-10 1988-04-07 Ortho Pharma Corp PROCEDURE FOR INCREASING THE HEMATOCRIT LEVEL FOR A NORMAL MAMMAL.
JPH03112934A (en) * 1989-09-27 1991-05-14 Mitsubishi Kasei Corp Compression formable powdery composition
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
JPH09507867A (en) * 1994-11-17 1997-08-12 バクスター、インターナショナル、インコーポレイテッド Hemoglobin therapy in hemodialysis
DE19535571A1 (en) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Combined pharmaceutical preparations and their use for the treatment of hemodialysis patients
ATE257712T1 (en) * 1996-08-27 2004-01-15 Hemosol Inc INCREASED STIMULATION OF ERYTHROPOIESIS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645733B2 (en) 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions

Also Published As

Publication number Publication date
EP0996462B1 (en) 2004-08-04
US20050197281A1 (en) 2005-09-08
DE59811768D1 (en) 2004-09-09
BR9810267A (en) 2000-09-12
KR100519904B1 (en) 2005-10-10
EP0885613A1 (en) 1998-12-23
KR20010014075A (en) 2001-02-26
JP2007246530A (en) 2007-09-27
JP2011246474A (en) 2011-12-08
ES2226151T3 (en) 2005-03-16
JP5785008B2 (en) 2015-09-24
AU743475B2 (en) 2002-01-24
WO1998058660A1 (en) 1998-12-30
TR199903192T2 (en) 2000-05-22
CN1261282A (en) 2000-07-26
ATE272405T1 (en) 2004-08-15
PT996462E (en) 2004-12-31
CN1185010C (en) 2005-01-19
EP0996462A1 (en) 2000-05-03
DK0996462T3 (en) 2004-11-29
US6440932B1 (en) 2002-08-27
JP2002504913A (en) 2002-02-12
AU8109898A (en) 1999-01-04
US20020160956A1 (en) 2002-10-31
CA2294448C (en) 2007-12-11

Similar Documents

Publication Publication Date Title
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
EP0995434A3 (en) Medicinal aerosol formulations
CA2274485A1 (en) Medicinal composition
CA2203033A1 (en) Compounds and compositions for delivering active agents
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
AU1023788A (en) Therapeutic system for sparingly soluble active ingredients
IE852593L (en) Compositions containing anthracycline glycosides
AU6995794A (en) Aspb28 insulin crystals
CA2180554A1 (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
IE881916L (en) Press-coated dihydropyridine tablets
PH30982A (en) Optically active 5H-pyrrolo Ä3,4-bÜ pyrazine derivative, its preparation and pharmaceutical compositions containing it.
IL89748A (en) Pharmaceutical compositions for systemic transdermal administration, containing deprenyl
EP0645136A3 (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation.
AU2034395A (en) Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance
CA2058428A1 (en) Analgesic formulations
IE871584L (en) Sustained release capsule.
CA2030838A1 (en) Preparations containing l-carnitine
CA2117769A1 (en) Liposome composition
AU8096591A (en) Composition for solid pharmaceutical preparations containing active vitamins d3 and process for preparation thereof
IL106472A0 (en) Hydroxamic acid derivatives,their preparation and pharmaceutical compositions containing them
NZ230356A (en) 2',3'-dideoxy-5-ethynyl-3'-fluorouridine: preparatory processes and pharmaceutical compositions
AU3266197A (en) Transdermic systems containing 2 active ingredients in separate compartments, their preparation process and their use as medicaments
IL109430A0 (en) Hydroxamic acid derivatives, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180604